Y-mAbs Therapeutics, Inc. Announces Appointment of Sue Smith as Chief Commercial Officer, Effective January 1, 2022
December 17, 2021 at 06:03 am EST
Share
Y-mAbs Therapeutics, Inc. announced the appointment of Sue Smith as the Company's Senior Vice President and Chief Commercial Officer effective as of January 1, 2022. Ms. Smith has more than 25 years of U.S and global oncology and rare disease experience and for the past almost 10 years she was employed by Kyowa Kirin, Inc., most recently as Vice President, U.S Oncology Business Unit Head.
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Y-MABS THERAPEUTICS, INC. 
